Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2011 May 11;17(9):1265–1272. doi: 10.1016/j.bbmt.2011.05.002

Table 1.

Autologous stem cell transplantation outcome in transformed lymphoma.

Ref Year* No of
patients		 Median
age
(yr)		 No of
regimens
Median
(range)		 Conditioning
regimen		 Pre-SCT
disease
status
(CR+PR %)		 DFS/
PFS
(%)		 OS (%)
40 2010 12 47 2 (1-4) BuCy, CyTBI 91 33
(5 year)		 58
(5 year)
39 2009 25 57 2 (1-11) CBV 92 59
(3 year)		 64
(3 year)
42 2008 24 56 2 (1-6) BuCy, BEAM,
CBV		 75 33
(5 year)		 52
(5 year)
38 2007 23 49.6 2 CBV, BEAM n/a 25
(5 year)		 56
(5 year)
44 2001 50 40 1 (0-3) CyTBI±VP16,
BEAM or CBV		 CR=38 30
(5 year)		 51
(5 year)
37 2001 35 48 1 (0-4) VP16MelTBI 100 36
(5 year)		 37
(5 year)
18 1999 27 44 3 (2-10) CyTBI CR=44 46
(5 year)		 58
(5 year)
43 1998 27 42 3 (1-10) CyTBI 100 n/a n/a
45 1989 10 42 n/a CyTBI,
CyVP16B,
CyAra-CTBI		 80 n/a n/a

Ref, reference number;

*

, year of publication;

No, number; yr, year; SCT, stem cell transpla ntation; CR, complete remission; PR, partial remission; DFS, disease free survival; OS, overall survival; Cy, cyclophosphamide; VP16, etoposide; TBI, total body irradiation; BEAM, carmustine, etoposide, cytarabine, and melphalan; CBV, cyclophosphamide, carmustine, etoposide; BuCy, busulfan, cyclophosphamide; Mel, melphalan; Ara-C, cytarabine; PFS, progression free survival.